Silver Spring, MD - As if a black-box warning currently on the label were not enough to get anyone's attention, today the US Food and Drug Administration (FDA) again reminded clinicians that ...

Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

Please provide your email address to receive an email when new articles are posted on . More patients in the ED with hemoptysis saw an end to the condition with nebulized vs. IV tranexamic acid.

Please provide your email address to receive an email when new articles are posted on . No serious adverse events or deaths were linked to fasudil treatment. Efficacy may be best determined with ...

Clinicians have a range of options for treating patients with disease states that require the use of immunoglobulin (Ig). Traditionally, intravenous immunoglobulin (IVIG) administration has provided ...

The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, ...

Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...

Although nicotine is the main addictive chemical in tobacco, there have been few studies of pure nicotine self-administration in humans. The goal of this study was to test the parameters of an ...

The U.S. Food and Drug Administration (FDA) has approved the first medication delivered intravenously to reduce both episodic and chronic migraine. The FDA gave the go-ahead based on research showing ...

BETHLEHEM, Pa., Sept. 21, 2021 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today the launch of its new CARESAFETM IV Administration ...

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. We conducted a phase 1 clinical trial to ...